

Meeting Room 3&4
Hilton Sydney Hotel
488 George St
Sydney NSW 2000

12.30 – 1.00 pm	Registration	
1.00 – 1.05 pm	Welcome and introductions	N Pavlakis
1.05 – 2.30 pm	<p>Updates on trials and concepts in development</p> <ul style="list-style-type: none"> i. ALTG 14/001 BR.31 (McLachlan) ii. ALTG 14/002 NIVORAD (Mitchell) iii. ALTG 15/003 DREAM (Nowak) iv. ALTG 13/008 PEARL (Mileshkin) v. ALTG 15/004 BR.34 (TBD) vi. ALTG 16/002 fear of recurrence (McLachlan) vii. ALTG 16/003 optimal duration of immunotherapy (O'Byrne) viii. ALTG 16/004 immunotherapy in SCLC with brain metastases (Mitchell) ix. ALTG 16/005 OSCILLATE alternating osimertinib/gefitinib in EGFR T790M NSCLC (Solomon) x. ALTG 16/007 Alternating crizotinib/lorlatinib in ALK+ NSCLC (Pavlakis) xi. ALTG 16/008 Avelumab + nintedanib in NSCLC (Pavlakis) xii. ALTG 16/009 (b) Durvalumab + tremelimumab in relapsed EGFR mutant NSCLC (Lee) xiii. ALTG 16/010 Primary care vs hospital-based follow-up after surgical lobectomy for NSCLC (Brims) 	<p>S McLachlan P Mitchell P S Kok A Livingstone M Stockler P S Kok K O'Byrne P Mitchell B Solomon P Mitchell N Pavlakis N Pavlakis M Stockler TBC</p>
2.30 – 3.00 pm	Break	
3.00 – 3.30 pm	<p>New concepts for group consideration</p> <p>For endorsement: Activities and influence of the specialist lung cancer nurse: A mixed-method comparative study of the multidisciplinary team assigned and not assigned a specialist lung cancer nurse (Brunelli/ANZ LCNF)</p> <p>For participation: ETOP/IFCT 4-12 STIMULI</p>	<p>V Brunelli P Mitchell</p>
3.30 – 4.30 pm	Portfolio gap analysis and prioritisation	All
4.30 – 4.45 pm	Summary, next steps	N Pavlakis

Note: ALTG 16/006 ramucirumab + osimertinib in 2L EGFR T790M NSCLC (Mitchell) is not progressing